Literature DB >> 20530988

Serum autoimmune gastritis markers, pepsinogen I and parietal cell antibodies, in patients with type 1 diabetes mellitus: a 5-year prospective study.

N Alonso1, M L Granada, B Soldevila, I Salinas, C Joaquin, J L Reverter, J Juncà, E M Martínez Cáceres, A Sanmartí.   

Abstract

BACKGROUND AND AIM: To determine the temporal evolution of serum markers of autoimmune gastritis, mainly pepsinogen I (PI) and parietal cell antibodies (PCA), in patients with Type 1 diabetes mellitus (DM1).
MATERIALS AND METHODS: A 5-yr prospective follow-up study of 168 DM1 patients (87 men, aged 31 ± 9.3 yr) attending the endocrinology outpatient clinic of a university hospital evaluated in 2001 and 2006. Serum PI, gastrin, hemoglobin, cobalamin concentrations, PCA and antibodies to intrinsic factor were measured.
RESULTS: In 2001, 11 patients had low PI concentrations and positive PCA (group I), 11 had only low PI concentrations (group II), and 33 had only positive PCA (group III). After 5 yr, PI remained low and PCA positive in all patients from group I. In group II, PI remained low in 4 and normalized in 7. In group III, 4 patients presented low PI concentrations after 5 yr, which remained normal in the other 29 subjects. PCA became negative in 17 patients from group III. In 2001, 3 of the 11 patients of group I had low cobalamin concentrations. In 2006, 2 additional patients from this group presented low cobalamin concentrations.
CONCLUSIONS: These results show the importance of determining PI together with PCA, since the presence of abnormal results in both tests, that is low PI and positive PCA, is the association that best identifies patients with a higher risk to decrease cobalamin concentrations during follow-up.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20530988     DOI: 10.1007/BF03347456

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  21 in total

1.  ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract.

Authors:  William K Hirota; Marc J Zuckerman; Douglas G Adler; Raquel E Davila; James Egan; Jonathan A Leighton; Waqar A Qureshi; Elizabeth Rajan; Robert Fanelli; Jo Wheeler-Harbaugh; Todd H Baron; Douglas O Faigel
Journal:  Gastrointest Endosc       Date:  2006-04       Impact factor: 9.427

2.  Natural history of autoimmune achlorhydric atrophic gastritis. A 1-15-year follow-up study.

Authors:  W J Irvine; D R Cullen; H Mawhinney
Journal:  Lancet       Date:  1974-08-31       Impact factor: 79.321

3.  High prevalence of manifestations of gastric autoimmunity in parietal cell antibody-positive type 1 (insulin-dependent) diabetic patients. The Belgian Diabetes Registry.

Authors:  C E De Block; I H De Leeuw; L F Van Gaal
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

4.  Serum pepsinogen I: an early marker of pernicious anemia in patients with type 1 diabetes.

Authors:  Núria Alonso; M Luisa Granada; Isabel Salinas; Ana M Lucas; Jordi L Reverter; Jordi Juncà; Albert Oriol; Ana Sanmartí
Journal:  J Clin Endocrinol Metab       Date:  2005-07-19       Impact factor: 5.958

5.  Type 1 diabetes and latent pernicious anaemia.

Authors:  R E Davis; V J McCann; K G Stanton
Journal:  Med J Aust       Date:  1992-02-03       Impact factor: 7.738

Review 6.  Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994.

Authors:  M F Dixon; R M Genta; J H Yardley; P Correa
Journal:  Am J Surg Pathol       Date:  1996-10       Impact factor: 6.394

7.  Frequency of thyroid dysfunction in diabetic patients: value of annual screening.

Authors:  P Perros; R J McCrimmon; G Shaw; B M Frier
Journal:  Diabet Med       Date:  1995-07       Impact factor: 4.359

8.  Serum pepsinogen I and serum gastrin in the screening of severe atrophic corpus gastritis.

Authors:  M Kekki; I M Samloff; K Varis; T Ihamäki
Journal:  Scand J Gastroenterol Suppl       Date:  1991

9.  Predictive value of gastric parietal cell autoantibodies as a marker for gastric and hematologic abnormalities associated with insulin-dependent diabetes.

Authors:  W J Riley; P P Toskes; N K Maclaren; J H Silverstein
Journal:  Diabetes       Date:  1982-12       Impact factor: 9.461

10.  Autoimmune gastropathy in type 1 diabetic patients with parietal cell antibodies: histological and clinical findings.

Authors:  Christophe E M De Block; Ivo H De Leeuw; Johannes J P M Bogers; Paul A Pelckmans; Margareta M Ieven; Eric A E Van Marck; Kristien L Van Acker; Luc F Van Gaal
Journal:  Diabetes Care       Date:  2003-01       Impact factor: 19.112

View more
  4 in total

Review 1.  Cutting edge issues in autoimmune gastritis.

Authors:  Ban-Hock Toh; James Chan; Tin Kyaw; Frank Alderuccio
Journal:  Clin Rev Allergy Immunol       Date:  2012-06       Impact factor: 8.667

Review 2.  Pathophysiology and laboratory diagnosis of pernicious anemia.

Authors:  Ban-Hock Toh
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

3.  Increase of Deep Intraepithelial Lymphocytes in the Oxyntic Mucosa of Patients With Potential and Overt Autoimmune Gastritis.

Authors:  Marco Vincenzo Lenti; Alessandro Vanoli; Emanuela Miceli; Giovanni Arpa; Michele Di Stefano; Simone Soriano; Francesca Capuano; Antonella Gentile; Nicola Aronico; Luigi Coppola; Alessandra Pasini; Ombretta Luinetti; Aurelio Mauro; Marco Paulli; Catherine Klersy; Gino Roberto Corazza; Antonio Di Sabatino
Journal:  Front Immunol       Date:  2022-05-04       Impact factor: 8.786

4.  Luminescent Immunoprecipitation System (LIPS) for Detection of Autoantibodies Against ATP4A and ATP4B Subunits of Gastric Proton Pump H+,K+-ATPase in Atrophic Body Gastritis Patients.

Authors:  Edith Lahner; Cristina Brigatti; Ilaria Marzinotto; Marilia Carabotti; Giulia Scalese; Howard W Davidson; Janet M Wenzlau; Emanuele Bosi; Lorenzo Piemonti; Bruno Annibale; Vito Lampasona
Journal:  Clin Transl Gastroenterol       Date:  2017-01-19       Impact factor: 4.488

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.